Dose related growth response to indometacin☆ in Gitelman syndrome
Dose related growth response to indometacin☆ in Gitelman syndrome
复制标题
DOI：
10.1136/adc.81.6.508
复制
发表时间：
1999-12-01
影响因子：
5.2
通讯作者：
Coulthard, MG
中科院分区：
文献类型：
--
作者：
Liaw, LCT;Banerjee, K;Coulthard, MG
生长障碍是Gitelman综合征的一个公认特征，尽管它不像Bartter综合征那样频繁。据报道，吲哚美辛可改善Bartter综合征的生长，但对推荐补充镁的Gitelman综合征无效。本文报告3例Gitelman综合征姐妹篇，不能耐受镁补充剂，经服用吲哚美辛2 mg/kg/d后，低血压和多尿症状消失，但生长发育不良。然而，将吲哚美辛剂量增加至4 mg/kg/天显著改善了它们的生长，而没有改变它们的症状或生物化学。胃肠道出血需要使用米索前列醇。
Growth failure is a recognised feature of Gitelman syndrome, although it is not as frequent as in Bartter syndrome. Indometacin is reported to improve growth in Bartter syndrome, hut not in Gitelman syndrome, where magnesium supplements are recommended. This paper presents 3 sisters with Gitelman syndrome who could not tolerate magnesium supplements, and whose hypotension and polyuria were eliminated by taking 2 mg/kg/day indometacin, bur who grew poorly. However, increasing the indometacin dose to 4 mg/kg/day improved their growth significantly, without changing their symptoms or biochemistry. Gastrointestinal haemorrhage necessitated the use of misoprostol.